Nintedanib, a selective inhibitor of tumor angiogenesis by blocking receptors activities such as VEGFR1C3, PDGFR- and -, and FGFR1C3, was proposed to treat nonCsmall cell lung adenocarcinoma and idiopathic lung fibrosis (Hilberg et al., 2018). in physiological and pathological angiogenesis and analyze current knowledge on how deregulation of epigenetic modifiers […]
Daily Archives: February 2, 2022
1 post